Comparison · NCT00901901-cf7ea468
Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva) vs Sorafenib (Nexavar, BAY 43-9006) + Placebo: Disease Control
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva) vs Sorafenib (Nexavar, BAY 43-9006) + Placebo: Disease Control. Trial comparisons, record NCT00901901-cf7ea468. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00901901-cf7ea468
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.439 | 0.389 | 0.491 | wilson | |
| Risk in group 2 | 0.525 | 0.473 | 0.576 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0859 | -0.158 | -0.0129 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.836 | 0.718 | 0.974 | log | |
| Odds ratio, group 1 over group 2 | 0.708 | 0.528 | 0.95 | log | |
| Number needed to treat, for one fewer participant with the outcome on Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva) than on Sorafenib (Nexavar, BAY 43-9006) + Placebo | 11.6 | 6.34 | 77.4 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva) | Participants received sorafenib 400 mg twice daily (bid) and erlotinib 150 mg tablet once daily (qd) | 159 | 362 | OG000 |
| Group 2 | Sorafenib (Nexavar, BAY 43-9006) + Placebo | Participants received sorafenib 400 mg twice daily (bid) and matching erlotinib placebo 150 mg tablet once daily (qd) | 188 | 358 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Disease Control
- Description
Disease control was defined as the number of participants who had a best response rating of complete response (CR), partial response (PR), or stable disease (SD) according to RECIST assessed by magnetic resonance imaging (MRI) that was confirmed at least 28 days from the first demonstration of that rating. CR: disappearance of all clinical and radiological evidence of target and non-target tumors. PR: at least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD. SD: steady state of disease. Neither sufficient shrinkage for PR nor sufficient increase for PD.
- Time frame
- From randomization of the first participant until 34 months later (cut-off date), assessed every 6 weeks
- Population
- The full analysis set (FAS), which was defined as all randomized participants
Source ClinicalTrials.gov
Trial
- Title
- Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
- NCT number
- NCT00901901
- Phases
- PHASE3
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Sorafenib (Nexavar, BAY43-9006), Erlotinib (Tarceva), Placebo
- Lead sponsor
- Bayer
- Results first posted
- 2013-09-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00901901?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00901901-cf7ea468